News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Ayush is expanding beyond wellness to therapeutic wellness
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Development services for gene and cell therapies is planned to begin first in 2025
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Subscribe To Our Newsletter & Stay Updated
